Found 11 articles for: "Lupus"
Bruton Tyrosine Kinase Inhibitors for Systemic Lupus Erythematosus: A Systematic Review of Randomized Controlled Trials
November 2026 | Volume 25 | Issue 11 | Original Article | 1039 | Copyright © November 2026
Background: Systemic lupus erythematosus (SLE) is a chronic relapsing autoimmune disease with frequent cutaneous involvement and unmet treatment need. Given safety and efficacy c...
Read MoreEyebrow Madarosis: An Updated Review of the Etiology and Management, Part II– Scarring Disorders
September 2026 | Volume 25 | Issue 9 | Original Article | 852 | Copyright © September 2026
Background: Eyebrows play an essential role in facial symmetry, communication, and aesthetic identity. Scarring eyebrow alopecia results from inflammatory, autoimmune, infectious...
Read MoreDifferentiating and Managing Cutaneous Lupus Erythematosus-Associated Alopecia and Patchy Alopecia Areata: Therapeutic Insights From Case Studies
March 2025 | Volume 24 | Issue 3 | Case Reports | 324 | Copyright © March 2025
Cutaneous lupus erythematosus (CLE) is an autoimmune disease with diverse clinical manifestations, including patchy hair lossresembling alopecia areata (AA). This report describes tw...
Read MoreThe Role of JAK Inhibitors in the Treatment of Cutaneous Lupus Erythematosus: A Review
December 2024 | Volume 23 | Issue 12 | Original Article | 1100 | Copyright © December 2024
Cutaneous lupus erythematosus (CLE), a manifestation of the chronic autoimmune disease lupus erythematosus (LE), showcases diverse clinical, immunologic, and histologic attributes. CLE can be fur...
Read MorePruritus in Lupus Patients
December 2023 | Volume 22 | Issue 12 | Editorials | e35 | Copyright © December 2023
Open-Label Phase 2 Pilot Study of Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE)
April 2023 | Volume 22 | Issue 4 | Features | 425 | Copyright © April 2023
Citation: Alsukait S, Learned C, Rosmarin D. Open-label phase 2 pilot study of oral tofacitinib in adult subjects with Discoid Lupus Erythematosus (DLE). J Drugs Dermatol. 2023;22(4)...
Read MoreConcurrent Interstitial Granulomatous Dermatitis and TNF-α Antagonist-Induced Lupus Syndrome Secondary to Adalimumab for Crohn's Disease
November 2022 | Volume 21 | Issue 11 | Case Reports | 1256 | Copyright © November 2022
Tumor necrosis factor (TNF) antagonists have revolutionized management for various autoimmune and inflammatory conditions, including rheumatoid arthritis (RA), inflammatory bowel disease, hidradenitis...
Read MoreA Retrospective Study of Calcinosis Cutis in Patients With Systemic Lupus Erythematosus
October 2022 | Volume 21 | Issue 10 | Editorials | 1137 | Copyright © October 2022
Calcinosis cutis (CC) is a very rare and poorly characterized finding in systemic lupus erythematosus (SLE).1 In this retrospective study, we present our experience of 10 individuals with S...
Read MorePlatelet Rich Plasma for the Treatment of Scarring Alopecia Due to Discoid Lupus Erythematosus
March 2022 | Volume 21 | Issue 3 | Case Reports | 309 | Copyright © March 2022
Platelet-rich plasma (PRP) is an autologous concentration of plasma from a patient’s blood containing platelets up to 7 times higher than normal plasma. Originally indicated to improve connectiv...
Read MoreTreatment of Hyperpigmented Discoid Lupus Erythematosus With Jessner's Peel: A Case Report
January 2022 | Volume 21 | Issue 1 | Case Reports | 92 | Copyright © January 2022
Discoid lupus erythematosus (DLE) is the most common type of chronic cutaneous lupus erythematosus and is categorized by well-demarcated, often hyper or hypopigmented macules or papules that gradually...
Read MoreCharacterization and Clinical Significance of Non-Scarring Alopecia in Systemic Lupus Erythematosus
May 2021 | Volume 20 | Issue 5 | Editorials | 584 | Copyright © May 2021
© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
